Ofatumumab is a human monoclonal antibody which targets an epitope in the CD20 molecule encompassing parts of the small and large extracellular loops. Ofatumumab is marketed and developed under a co-development and commercialization agreement with Novartis Pharma AG.  

Marketed indications and safety
Ofatumumab is approved as ARZERRA® in certain territories to treat certain chronic lymphocytic leukemia (CLL) indications. Please consult the full U.S. Prescribing information, including Boxed Warning for all the labeled safety information for ARZERRA. 

Clinical studies
A subcutaneous formulation of ofatumumab is being investigated for use in relapsing multiple sclerosis (RMS). Ofatumumab is being studied in clinical trials, including Investigator Sponsored Studies (ISS); for more information visit clinicaltrials.gov